Exelixis, Inc. (0IJO.L)
USD 34.24
(-1.28%)
USD 34.24
(-1.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.58 Billion USD | 17.39% |
| 2022 | 1.35 Billion USD | 23.39% |
| 2021 | 1.09 Billion USD | 30.22% |
| 2020 | 841.2 Million USD | 48.83% |
| 2019 | 565.2 Million USD | 45.44% |
| 2018 | 388.62 Million USD | 43.12% |
| 2017 | 271.53 Million USD | 28.01% |
| 2016 | 212.11 Million USD | 38.04% |
| 2015 | 153.65 Million USD | -35.96% |
| 2014 | 239.93 Million USD | 4.44% |
| 2013 | 229.72 Million USD | 42.94% |
| 2012 | 160.71 Million USD | -15.4% |
| 2011 | 189.96 Million USD | -22.05% |
| 2010 | 243.69 Million USD | -10.95% |
| 2009 | 273.66 Million USD | -8.43% |
| 2008 | 298.85 Million USD | -2.8% |
| 2007 | 307.45 Million USD | 36.39% |
| 2006 | 225.42 Million USD | 32.64% |
| 2005 | 169.95 Million USD | 6.61% |
| 2004 | 159.4 Million USD | 8.53% |
| 2003 | 146.87 Million USD | 11.74% |
| 2002 | 131.43 Million USD | 19.87% |
| 2001 | 109.64 Million USD | 27.17% |
| 2000 | 86.22 Million USD | 146.34% |
| 1999 | 35 Million USD | 99.23% |
| 1998 | 17.56 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 343.16 Million USD | 0.44% |
| 2024 Q3 | 403.46 Million USD | 12.52% |
| 2024 Q1 | 341.67 Million USD | -9.16% |
| 2023 FY | 1.58 Billion USD | 17.39% |
| 2023 Q3 | 470.72 Million USD | 20.08% |
| 2023 Q2 | 391.99 Million USD | 7.21% |
| 2023 Q1 | 365.64 Million USD | -19.83% |
| 2023 Q4 | 376.11 Million USD | -20.1% |
| 2022 Q2 | 322.24 Million USD | 24.16% |
| 2022 Q1 | 259.53 Million USD | -19.29% |
| 2022 Q3 | 313.82 Million USD | -2.61% |
| 2022 Q4 | 456.07 Million USD | 45.33% |
| 2022 FY | 1.35 Billion USD | 23.39% |
| 2021 FY | 1.09 Billion USD | 30.22% |
| 2021 Q1 | 261.63 Million USD | 10.53% |
| 2021 Q2 | 247.28 Million USD | -5.49% |
| 2021 Q4 | 321.57 Million USD | 21.38% |
| 2021 Q3 | 264.92 Million USD | 7.13% |
| 2020 Q2 | 174.72 Million USD | 6.01% |
| 2020 Q3 | 264.94 Million USD | 51.64% |
| 2020 Q4 | 236.71 Million USD | -10.65% |
| 2020 FY | 841.2 Million USD | 48.83% |
| 2020 Q1 | 164.81 Million USD | 8.1% |
| 2019 Q1 | 123.42 Million USD | 12.57% |
| 2019 FY | 565.2 Million USD | 45.44% |
| 2019 Q4 | 152.47 Million USD | 2.63% |
| 2019 Q3 | 148.56 Million USD | 5.55% |
| 2019 Q2 | 140.74 Million USD | 14.03% |
| 2018 Q1 | 90.4 Million USD | 15.23% |
| 2018 FY | 388.62 Million USD | 43.12% |
| 2018 Q4 | 109.64 Million USD | 18.08% |
| 2018 Q3 | 92.86 Million USD | -1.57% |
| 2018 Q2 | 94.34 Million USD | 4.36% |
| 2017 Q4 | 78.45 Million USD | 17.67% |
| 2017 Q1 | 57.47 Million USD | 56.16% |
| 2017 FY | 271.53 Million USD | 28.01% |
| 2017 Q3 | 66.67 Million USD | -3.29% |
| 2017 Q2 | 68.94 Million USD | 19.96% |
| 2016 Q3 | 52.71 Million USD | -10.35% |
| 2016 Q1 | 63.78 Million USD | 57.04% |
| 2016 FY | 212.11 Million USD | 38.04% |
| 2016 Q4 | 36.8 Million USD | -30.19% |
| 2016 Q2 | 58.8 Million USD | -7.8% |
| 2015 Q2 | 37.29 Million USD | 17.23% |
| 2015 FY | 153.65 Million USD | -35.96% |
| 2015 Q4 | 40.61 Million USD | -7.55% |
| 2015 Q3 | 43.93 Million USD | 17.8% |
| 2015 Q1 | 31.81 Million USD | -35.62% |
| 2014 FY | 239.93 Million USD | 4.44% |
| 2014 Q4 | 49.41 Million USD | -7.69% |
| 2014 Q3 | 53.53 Million USD | -20.62% |
| 2014 Q2 | 67.44 Million USD | -3.01% |
| 2014 Q1 | 69.53 Million USD | 9.97% |
| 2013 FY | 229.72 Million USD | 42.94% |
| 2013 Q4 | 63.23 Million USD | 3.74% |
| 2013 Q3 | 60.95 Million USD | -2.1% |
| 2013 Q2 | 62.25 Million USD | 43.85% |
| 2013 Q1 | 43.28 Million USD | 2.27% |
| 2012 Q4 | 42.32 Million USD | 11.3% |
| 2012 FY | 160.71 Million USD | -15.4% |
| 2012 Q1 | 41 Million USD | 8.5% |
| 2012 Q2 | 39.37 Million USD | -3.98% |
| 2012 Q3 | 38.02 Million USD | -3.42% |
| 2011 Q4 | 37.78 Million USD | -17.2% |
| 2011 FY | 189.96 Million USD | -22.05% |
| 2011 Q3 | 45.63 Million USD | -11.7% |
| 2011 Q2 | 51.68 Million USD | -5.78% |
| 2011 Q1 | 54.85 Million USD | 14.37% |
| 2010 Q2 | 63.8 Million USD | -13.29% |
| 2010 Q4 | 47.96 Million USD | -17.78% |
| 2010 Q3 | 58.34 Million USD | -8.57% |
| 2010 Q1 | 73.58 Million USD | -1.07% |
| 2010 FY | 243.69 Million USD | -10.95% |
| 2009 Q1 | 62.07 Million USD | -12.02% |
| 2009 Q4 | 74.38 Million USD | 3.6% |
| 2009 Q3 | 71.79 Million USD | 9.75% |
| 2009 Q2 | 65.41 Million USD | 5.38% |
| 2009 FY | 273.66 Million USD | -8.43% |
| 2008 Q2 | 79.09 Million USD | 5.94% |
| 2008 Q1 | 74.66 Million USD | -17.17% |
| 2008 FY | 298.85 Million USD | -2.8% |
| 2008 Q4 | 70.55 Million USD | -5.34% |
| 2008 Q3 | 74.53 Million USD | -5.77% |
| 2007 Q4 | 90.14 Million USD | 2.13% |
| 2007 Q2 | 67.56 Million USD | 9.87% |
| 2007 Q1 | 61.49 Million USD | -3.2% |
| 2007 FY | 307.45 Million USD | 36.39% |
| 2007 Q3 | 88.25 Million USD | 30.64% |
| 2006 Q1 | 49.17 Million USD | 12.09% |
| 2006 Q4 | 63.52 Million USD | 15.29% |
| 2006 Q3 | 55.1 Million USD | -4.38% |
| 2006 Q2 | 57.62 Million USD | 17.18% |
| 2006 FY | 225.42 Million USD | 32.64% |
| 2005 Q3 | 42.29 Million USD | -3.78% |
| 2005 Q1 | 39.83 Million USD | -1.55% |
| 2005 Q4 | 43.87 Million USD | 3.74% |
| 2005 FY | 169.95 Million USD | 6.61% |
| 2005 Q2 | 43.95 Million USD | 10.34% |
| 2004 Q3 | 39.3 Million USD | 0.04% |
| 2004 Q2 | 39.28 Million USD | -1.7% |
| 2004 FY | 159.4 Million USD | 8.53% |
| 2004 Q1 | 39.96 Million USD | 8.14% |
| 2004 Q4 | 40.46 Million USD | 2.96% |
| 2003 Q1 | 35.63 Million USD | 9.02% |
| 2003 Q2 | 37.32 Million USD | 4.73% |
| 2003 Q3 | 36.95 Million USD | -0.97% |
| 2003 FY | 146.87 Million USD | 11.74% |
| 2003 Q4 | 36.95 Million USD | -0.01% |
| 2002 Q1 | 31.46 Million USD | -0.24% |
| 2002 Q4 | 32.68 Million USD | -2.15% |
| 2002 FY | 131.43 Million USD | 19.87% |
| 2002 Q3 | 33.4 Million USD | 1.34% |
| 2002 Q2 | 32.96 Million USD | 4.77% |
| 2001 Q3 | 29.22 Million USD | 9.22% |
| 2001 Q2 | 26.75 Million USD | 12.1% |
| 2001 Q1 | 23.86 Million USD | 6.03% |
| 2001 Q4 | 31.54 Million USD | 7.93% |
| 2001 FY | 109.64 Million USD | 27.17% |
| 2000 Q4 | 22.51 Million USD | 2.86% |
| 2000 Q1 | 17.27 Million USD | 0.0% |
| 2000 Q2 | 24.54 Million USD | 42.09% |
| 2000 FY | 86.22 Million USD | 146.34% |
| 2000 Q3 | 21.88 Million USD | -10.84% |
| 1999 FY | 35 Million USD | 99.23% |
| 1998 FY | 17.56 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -541.63% |
| Dynavax Technologies Corporation | 219.14 Million USD | -624.076% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -199.951% |
| Perrigo Company plc | 1.52 Billion USD | -3.813% |
| Illumina, Inc. | 3.81 Billion USD | 58.385% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 84.525% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -251.84% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 96.092% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 22.709% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1215.113% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 43.637% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3452.457% |
| Waters Corporation | 943.51 Million USD | -68.177% |
| Biogen Inc. | 5.2 Billion USD | 69.514% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -593.885% |
| Evolus, Inc. | 189.75 Million USD | -736.206% |
| Adicet Bio, Inc. | 152.03 Million USD | -943.671% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1013.816% |
| bluebird bio, Inc. | 240.23 Million USD | -560.518% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -483.595% |
| FibroGen, Inc. | 398.11 Million USD | -298.574% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 24.975% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -11307.742% |
| Homology Medicines, Inc. | 9.87 Million USD | -15968.618% |
| Geron Corporation | 70.44 Million USD | -2152.631% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 11.849% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -271.045% |
| Myriad Genetics, Inc. | 600.1 Million USD | -164.419% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1473.761% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -187.686% |
| Zoetis Inc. | 2.76 Billion USD | 42.612% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -3171.568% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -45.657% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 9.134% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 66.769% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -3952.757% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -103.541% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -475.559% |
| Verastem, Inc. | 92.08 Million USD | -1623.183% |
| Nektar Therapeutics | 190.9 Million USD | -731.195% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -233.104% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -12969.566% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -16.605% |
| OPKO Health, Inc. | 574.68 Million USD | -176.112% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 0.609% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -330.473% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2745.929% |
| uniQure N.V. | 285.08 Million USD | -456.596% |
| Imunon, Inc. | 21.03 Million USD | -7445.143% |
| Blueprint Medicines Corporation | 722.86 Million USD | -119.513% |
| Insmed Incorporated | 949.26 Million USD | -67.159% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -430.13% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -288.149% |
| TG Therapeutics, Inc. | 198.47 Million USD | -699.484% |
| Incyte Corporation | 1.19 Billion USD | -33.287% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -51.99% |